One Month of Brief Weekly Magnetic Field Therapy Enhances the Anticancer Potential of Female Human Sera: Randomized Double-Blind Pilot Study.

Preclinical studies have shown that the blood from female mice exposed weekly to magnetic fields inhibited breast cancer growth. This double-blind randomized controlled trial investigated whether analogous magnetic therapy could produce similar anticancer sera from human subjects. Twenty-six healthy adult females (ages 30-45) were assigned to either a magnetic therapy group, receiving twice weekly 1 mT magnetic exposures (10 min/session) for 4 weeks, or a control group, who underwent identical sham exposure. Blood sera were evaluated for their capacity to modulate breast cancer-related cellular responses and epithelial-mesenchymal transition. The sera from the magnetic therapy group subjects exhibited significant anticancer effects that were strongest one month after the last magnetic exposure, whereas the sera from unexposed females or unexposed or exposed males showed no effect. Female sera from the magnetic therapy group (n = 12) reduced breast cancer cell proliferation (16.1%), migration (11.8%) and invasion (28.2%) and reduced the levels of key EMT markers relative to the control sera (n = 14). Magnetic therapy modulated the serum levels of angiogenic and myogenic biomarkers in a manner consistent with improved cancer management. Muscle-targeted magnetic therapy holds the potential to enhance the anticancer properties of human blood via an adaptive process, akin to exercise training.